Evidence map›Paper›PMID 38509699›Full record

Trial reportHuman vaccines & immunotherapeutics2024

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.

Shaomin Chen, Zhifang Ying, Yan Liu, Yuan Li, Yebin Yu, Meilian Huang, Zhuhang Huang, Zhiqiang Ou, Yuyi Liao, Yong Zhang and 11 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04481191 (A Phase 3 Randomized, Open-Label, Clinical Trial to Study the Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of V260 and Inactivated Poliomyelitis Vaccine), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04481191 phase3completednot on this map

A Phase 3 Randomized, Open-Label, Clinical Trial to Study the Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of V260 and Inactivated Poliomyelitis Vaccine (IPV) in Chinese Healthy Infants

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2020 to 2021Enrolled400ConditionsPrevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9ArmsRotaTeq (V260), IPV
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 4 countries.

Shaomin ChenBiological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.
Zhifang YingRespiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
Yan LiuDivision of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
Yuan LiBiological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.
Yebin YuVaccine Clinical Research Office, Yangchun Center for Disease Control and Prevention, Yangchun, Guangdong, China.
Meilian HuangVaccine Clinical Research Office, Yangchun Center for Disease Control and Prevention, Yangchun, Guangdong, China.
Zhuhang HuangBiological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.
Zhiqiang OuBiological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.
Yuyi LiaoBiological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.
Yong ZhangDivision of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
Guixiu LiuClinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China.
Weiwei ZhaoBiostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China.
Rong FuBiostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China.
Qiong ShouBiostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China.
Minghuan ZhengClinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China.
Xueyan LiaoClinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China.
Yingmei TuInfectious Diseases/Vaccines Clinical Research, Merck & Co. Inc., Rahway, NJ, USA.
Jon StekInfectious Diseases/Vaccines Clinical Research, Merck & Co. Inc., Rahway, NJ, USA.
Jonathan HartzelBiostatistics and Research Decision Sciences, Merck & Co. Inc., Rahway, NJ, USA.
Changgui LiInstitute for Control of Biological Products, National Institutes for Food and Drug Control, Beijing, China.
Jikai ZhangDirectors Office, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.
Guangdong Institute of Biological Products and Drugs · CNMSD K.K. (Japan) · JPNational Institutes for Food and Drug Control · CNMerck & Co., Inc., Rahway, NJ, USA (United States) · USCenter for Disease Control · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants. The primary objective was the non-inferiority of neutralizing antibody (nAb) responses in the concomitant- versus the staggered-use groups. Antibody responses were measured at baseline and 1-month post-dose 3 (PD3). Parents/legal guardians recorded adverse events for 30 or 15 d after study vaccinations in the concomitant-use or staggered-use groups, respectively. At PD3, >98% of participants seroconverted to all three poliovirus types, and the primary objective was met as lower bounds of the two-sided 95% CI for between-group difference in nAb seroconversion percentages ranged from - 4.3% to - 1.6%, for all poliovirus types,

Indexed as

PoliomyelitisPoliovirusRotavirus VaccinesAntibodies, NeutralizingAntibodies, ViralChinaHumansImmunogenicity, VaccineInfantPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralRotavirus VaccinesVaccines, Attenuatedconcomitantgastroenteritisimmunogenicityinactivated polio vaccinepentavalent rotavirus vaccinePoliomyelitissafety

Identifiers

PMID38509699
PMCPMC10962606
OpenAlexW4393054356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.